Cellectar Biosciences is working on testing a radiosensitive therapy in blood cancers including multiple Myeloma. Their product, CLR 131, targets the myeloma tumors by delivering a cytotoxic radioisotope, iodine-131 directly to the tumor cells. In a recent press release. they announced updated Phase I study results showing an overall mean survival rate of 26.2 months for [...]